Takeda Clears Key Hurdle as Investors Back $59 Billion Shire Deal

Takeda Clears Key Hurdle as Investors Back $59 Billion Shire Deal
The logo of Takeda Pharmaceutical Co. Japan May 9, 2018. Kim Kyung-Hoon/Reuters
|Updated:

OSAKA—Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.

Takeda will be joining the ranks of the world’s top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company.